Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation

Inflamm Res. 2010 Jun;59(6):463-9. doi: 10.1007/s00011-009-0146-z. Epub 2009 Dec 10.

Abstract

Aim: To study plasma YKL-40 in patients with atrial fibrillation (AF) treated with radiofrequency (RF) catheter ablation and to assess the predictive role of plasma YKL-40 and its changes after restoration of sinus rhythm (SR).

Methods: Forty-six patients (mean age 55 years, range 31-81) with paroxysmal/persistent AF were treated with RF catheter ablation; Holter monitoring for 14 days was performed before ablation and after 3 months. Recurrent symptomatic AF or atrial tachycardia >10 min was considered failure, and the patients were offered a second ablation session. YKL-40 was determined in plasma samples taken prior to ablation and at follow-up visits up to 12 months after ablation.

Results: After a maximum of two ablations, 19 patients (41%) had SR without recurrence of AF after 12 months. The patients with no recurrence of AF had significantly lower baseline plasma levels of YKL-40 prior to ablation compared to patients with recurrence of AF (31 vs. 62 microg/l, P = 0.029). Plasma YKL-40 was not an independent predictor of recurrence of AF after ablation. No significant changes in plasma YKL-40 levels were seen from baseline to follow-up at 12 months.

Conclusion: In patients with paroxysmal or persistent AF treated with catheter ablation, high plasma YKL-40 before ablation is associated with recurrence of AF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipokines
  • Adult
  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / blood*
  • Atrial Fibrillation / surgery*
  • Biomarkers
  • Catheter Ablation*
  • Chitinase-3-Like Protein 1
  • Electrocardiography
  • Electrocardiography, Ambulatory
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Follow-Up Studies
  • Glycoproteins / blood*
  • Humans
  • Lectins / blood*
  • Logistic Models
  • Male
  • Middle Aged
  • Recurrence
  • Treatment Outcome

Substances

  • Adipokines
  • Biomarkers
  • CHI3L1 protein, human
  • Chitinase-3-Like Protein 1
  • Glycoproteins
  • Lectins